ReviewCurrent atherosclerosis reports2026
Tangier Disease.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe describe two patients with Tangier disease (TD) and provide a narrative review of its clinical features, genetics, diagnosis, and management. A literature search of PubMed and Google Scholar was performed to identify English-language publications on TD, and relevant articles were reviewed narratively. RECENT
findingsPatient # 1 was diagnosed with TD due to compound heterozygous variant in ABCA1 (one pathogenic variant (c.1759 C > T, p.Arg587Trp) and one variant of uncertain significance (VUS) (c.1733 C > G, p.Pro578Arg)) when evaluated for histopathological findings of tonsillectomy specimen suggestive of TD. Patient # 2 was found to have TD due to homozygous pathogenic variant in ABCA1 (c.1769G > T p. Trp590Leu) when evaluated for incidental detection of low high density lipoprotein (HDL-C). TD, characterized by HDL-C deficiency affects reverse cholesterol transport causing intracellular cholesterol accumulation in various tissues producing characteristic clinical presentation. There is no definite treatment for TD. To the best of our knowledge the VUS noted in patient # 1 is likely pathogenic. This report will aid a variant reclassification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.